{"id":"NCT03695237","sponsor":"AbbVie","briefTitle":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","officialTitle":"A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45 mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-24","primaryCompletion":"2021-05-06","completion":"2023-11-29","firstPosted":"2018-10-04","resultsPosted":"2023-05-16","lastUpdate":"2024-05-29"},"enrollment":45,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Central Precocious Puberty (CPP)"],"interventions":[{"type":"DRUG","name":"Leuprolide Acetate (LA)","otherNames":["Lupron Depot"]}],"arms":[{"label":"Leuprolide Acetate (LA)","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.","primaryOutcome":{"measure":"Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24","timeFrame":"Week 24 (prior to the Week 24 dose); samples for LH measurement were taken 30 and 60 minutes after the stimulation test injection.","effectByArm":[{"arm":"Leuprolide Acetate - Previously Treated","deltaMin":94.4,"sd":null},{"arm":"Leuprolide Acetate - Treament Naïve","deltaMin":81.5,"sd":null},{"arm":"Leuprolide Acetate - Overall","deltaMin":86.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["http://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["INJECTION SITE PAIN","HEADACHE","INJECTION SITE REACTION","COVID-19","UPPER RESPIRATORY TRACT INFECTION"]}}